Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149868 | 1.00 | TSHR (1.00) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL5952125 | 0.98 | HCAR2 (1.00) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL1663622 | 0.94 | HCAR2 (1.00) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL31539683 | 0.83 | TSHR (0.71) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL22887837 | 0.83 | TSHR (0.71) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL25334427 | 0.81 | HCAR2 (0.70) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL14648769 | 0.81 | HCAR2 (0.70) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL18131065 | 0.79 | TSHR (0.65) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL21764920 | 0.77 | HCAR2 (0.70) | TSHRHCAR2KMT2ANPC1RAB9A | |
| SCHEMBL5083071 | 0.77 | HCAR2 (0.70) | TSHRHCAR2KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101592-B2 | Hexahydro-cyclooctyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2012-01-24 | — | — | US | disclosed |
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| WO-2005066135-A2 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | DDO, DAO, SRR | TSHR 1282/4885HCAR2 1744/4885KMT2A 1883/4885 |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | TSHR 1282/4885HCAR2 1744/4885KMT2A 1883/4885 |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | CHRNA7, CHRNA6, CHRNA5 | TSHR 354/4885HCAR2 57/4885KMT2A 3050/4885 |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | TSHR 1282/4885HCAR2 1744/4885KMT2A 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.